MG develops as the result of autoantibodies that target components of the NMJ, with various subtypes of MG classified by the antigen specificity of the autoantibody. The most common subtype of autoantibody-mediated MG, comprising approximately 85% of patients, is characterised by autoantibodies against the nicotinic acetylcholine receptor (AChR).
In other patients with MG, autoantibodies target muscle-specific kinase (MuSK) or low-density lipoprotein receptor–related protein 4. A small proportion of patients with MG do not have detectable circulating autoantibody levels to known targets, and these patients are diagnosed as having seronegative MG. Congenital, presynaptic autoimmune and thymoma-associated subtypes of MG exist, but their incidence is much rarer.
Learn more about the pathophysiology of MG.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Raghav Govindarajan, Nicholas J. Silvestri. Fast Five Quiz: Pathophysiology of Myasthenia Gravis - Medscape - Sep 15, 2023.